STAT+: Abridge inks deals with Nvidia and Lilly

Abridge, a startup valued at $5.3 billion, has secured new agreements with Nvidia and Eli Lilly to strengthen its position in a competitive market. The company aims to transform its ambient AI technology into a complete operating system for medicine. This expansion moves Abridge beyond simple clinical notes, integrating new capabilities for managing billing, conducting drug trials, and processing real-time insurance claims to provide a more comprehensive infrastructure for the healthcare industry.